What was the sale price range for Terrie Curran’s ARQT share sales?

The reported sale price is a weighted average of $25.0294 per share, with underlying transactions executed at prices ranging from $25.00 to $25.1001 per share.

Arcutis Biotherapeutics (ARQT) director sells 38K shares near $25

Q: What insider transactions did ARQT director Terrie Curran report on August 27, 2026?

Terrie Curran exercised stock options for 38,200 ARQT shares and sold the same 38,200 shares of common stock on August 27, 2026, according to the Form 4.

Q: How many Arcutis Biotherapeutics (ARQT) shares did Terrie Curran sell?

Terrie Curran sold a total of 38,200 shares of Arcutis Biotherapeutics common stock, consisting of two sales of 11,148 and 27,052 shares, respectively.

Q: At what prices were Terrie Curran’s ARQT options exercised?

Terrie Curran exercised stock options to acquire 11,148 shares at an exercise price of $7.51 per share and 27,052 shares at an exercise price of $8.63 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. director Terrie Curran reported option exercises and share sales. On August 27, 2026, Curran exercised stock options covering 38,200 shares of common stock at exercise prices of $7.51 and $8.63 per share, then sold the same 38,200 shares at a weighted average price of $25.0294 per share, with individual sale prices ranging from $25.00 to $25.1001.

Insider Trade Summary

Exercise and Sale: 38,200 shares ($639K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Curran Terrie

Role Director

Sold 38,200 shs ($956K)

Approx. gross sale proceeds $956K

Approx. exercise cost $317K

Approx. pre-tax spread $639K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F4}	11,148	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F3, F4}	27,052	$0.00	$0.00
Exercise	Common Stock ^F1	11,148	$7.51	$84K
Sale	Common Stock ^{F1, F2}	11,148	$25.0294	$279K
Exercise	Common Stock ^F3	27,052	$8.63	$233K
Sale	Common Stock ^{F3, F2}	27,052	$25.0294	$677K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 23,526 shares (Direct)

Footnotes (4)

F1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
F4. The option is fully vested.

Key Figures

Options Exercised Shares: 38,200 shares Exercise Price: $7.51 per share Exercise Price: $8.63 per share +4 more

7 metrics

Options Exercised Shares 38,200 shares Total common shares underlying options exercised on August 27, 2026

Exercise Price $7.51 per share Exercise price for 11,148-share option exercised on August 27, 2026

Exercise Price $8.63 per share Exercise price for 27,052-share option exercised on August 27, 2026

Shares Sold 38,200 shares Total common shares sold on August 27, 2026

Weighted Average Sale Price $25.0294 per share Weighted average sale price for shares sold within a $25.00–$25.1001 range

Option Expiration Date May 31, 2033 Expiration date of the 11,148-share option that was exercised

Option Expiration Date June 14, 2034 Expiration date of the 27,052-share option that was exercised

Key Terms

Stock Option (right to buy), weighted average sale price, non-employee director, fully vested, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

non-employee director financial

"subject to the non-employee director's continuous service."

fully vested financial

"The option is fully vested."

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

What insider transactions did ARQT director Terrie Curran report on August 27, 2026?

Terrie Curran exercised stock options for 38,200 ARQT shares and sold the same 38,200 shares of common stock on August 27, 2026, according to the Form 4.

How many Arcutis Biotherapeutics (ARQT) shares did Terrie Curran sell?

Terrie Curran sold a total of 38,200 shares of Arcutis Biotherapeutics common stock, consisting of two sales of 11,148 and 27,052 shares, respectively.

At what prices were Terrie Curran’s ARQT options exercised?

Terrie Curran exercised stock options to acquire 11,148 shares at an exercise price of $7.51 per share and 27,052 shares at an exercise price of $8.63 per share.

Were the stock options in the ARQT Form 4 fully vested before exercise?

Yes. The Form 4 footnotes state that the options exercised by Terrie Curran were fully vested on the exercise date, having vested 100% on the first anniversaries of May 31, 2023 and June 14, 2024, subject to continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/28/2026 - 05:40 PM Accepted by SEC EDGAR 08/28/2026 - 05:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curran Terrie

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/27/2026		M⁽¹⁾		11,148	A	$7.51	34,674	D
Common Stock	08/27/2026		S⁽¹⁾		11,148	D	$25.0294⁽²⁾	23,526	D
Common Stock	08/27/2026		M⁽³⁾		27,052	A	$8.63	50,578	D
Common Stock	08/27/2026		S⁽³⁾		27,052	D	$25.0294⁽²⁾	23,526	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.51	08/27/2026		M⁽¹⁾			11,148	⁽⁴⁾	05/31/2033	Common Stock	11,148	$0	0	D
Stock Option (right to buy)	$8.63	08/27/2026		M⁽³⁾			27,052	⁽⁴⁾	06/14/2034	Common Stock	27,052	$0	0	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

4. The option is fully vested.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR